Drugs for Optic Nerve Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 47)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
doxo Cell
doxo-Cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
|
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
2 |
|
Etoposide |
Approved |
Phase 2 |
|
33419-42-0 |
36462 |
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
eto GRY
eto-GRY
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
|
etoposide
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
etoposido Ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
3 |
|
Peginterferon alfa-2b |
Approved |
Phase 2 |
|
99210-65-8, 215647-85-1 |
|
Synonyms:
215647-85-1
D02748
Peginterferon alfa-2b
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
|
Peginterferon alfa-2b (INN)
PegIntron
PEG-Intron
Pegintron (TN)
Unitron PEG
|
|
4 |
|
Vincristine |
Approved, Investigational |
Phase 1, Phase 2 |
|
57-22-7, 2068-78-2 |
5978 |
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
Cellcristin
CHEBI:28445
CID5978
Citomid
D08679
DB00541
EINECS 200-318-1
Farmistin
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Onkocristin
|
PFS, Vincasar
Sulfate, vincristine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
vincristine
Vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine sulfate
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
Z-D-Val-Lys(Z)-OH
|
|
5 |
|
Sodium citrate |
Approved, Investigational |
Phase 1, Phase 2 |
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
6 |
|
Mebendazole |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
31431-39-7 |
4030 |
Synonyms:
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamate methyl ester
(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
(5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester
2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester
2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI)
31431-39-7
46404_FLUKA
46404_RIEDEL
5-Benzoyl-2-benzimidazolecarbamic acid methyl ester
5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester
AB00052203
abello Farmacia brand OF mebendazole
Abello Farmacia Brand of Mebendazole
AC-12064
AC1L1H98
AC1Q44DR
AKOS000539066
Anti worm
Anti Worm
Anti-worm
Anti-Worm
Ardeypharm brand OF mebendazole
Ardeypharm Brand of Mebendazole
Bantenol
Banworm
BAS 00341140
Besantin
BIDD:GT0087
Bio-0458
Bio-0803
Boots brand OF mebendazole
Boots Brand of Mebendazole
Boots threadworm treatment
Boots Threadworm Treatment
BPBio1_000257
BRD-K77987382-001-01-7
BRD-K77987382-001-06-6
BSPBio_000233
BSPBio_003178
Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester
Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI)
Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester
CAS-31431-39-7
CBDivE_010559
CCRIS 4479
CHEBI:6704
CHEMBL685
CID4030
CPD000036734
D00368
D008463
DB00643
Degort's brand OF mebendazole
Degort's Brand of Mebendazole
Diba brand OF mebendazole
Diba Brand of Mebendazole
DivK1c_000751
EINECS 250-635-4
Elfar brand OF mebendazole
Elfar Brand of Mebendazole
Equivurm Plus
Esteve brand OF mebendazole
Esteve Brand of Mebendazole
Healthypharm brand OF mebendazole
Healthypharm Brand of Mebendazole
HMS1536H11
HMS1568L15
HMS1921F03
HMS2090B03
HMS2092B15
HMS502F13
HSDB 3232
I06-2075
IDI1_000751
Janssen brand OF mebendazole
Janssen Brand of Mebendazole
KBio1_000751
KBio2_001778
KBio2_004346
KBio2_006914
KBio3_002398
KBioGR_000712
KBioSS_001778
Leidapharm brand OF mebendazole
Leidapharm Brand of Mebendazole
Lomper
LS-48951
M2523_FLUKA
M2523_SIGMA
Madicure
MBDZ
Mebendan
Mebendazol
Mebendazol [INN-Spanish]
mebendazole
|
Mebendazole
Mébendazole
Mebendazole (JAN/USP)
Mebendazole (JAN/USP/INN)
Mebendazole [USAN:INN:BAN:JAN]
Mebendazole(USAN)
MEBENDAZOLE, 99%
Mebendazolum
Mebendazolum [INN-Latin]
Mebenoazole
Mebenvet
Mebex
Mebutar
methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate
methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate
Methyl 5-benzoyl benzimidazole-2-carbamate
Methyl 5-benzoyl-2-benzimidazolecarbamate
Methyl 5-benzoyl-2-benzimidazolylcarbamate
Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate
Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate
MLS000028491
MolPort-000-765-625
MolPort-001-889-615
N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle
N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]
N-2 (5-Benzoyl-benzimidazole) carbamate de methyle
N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]
NCGC00016806-01
NCGC00016806-02
NCGC00021698-03
NCGC00021698-04
NCGC00021698-05
NCGC00021698-06
NINDS_000751
Norgine brand OF mebendazole
Norgine Brand of Mebendazole
Noverme
NSC 184849
NSC184849
Oprea1_278237
Oprea1_768530
Ovitelmin
Pantelmin
Pfizer brand OF mebendazole
Pfizer Brand of Mebendazole
Prestwick_310
Prestwick0_000217
Prestwick1_000217
Prestwick2_000217
Prestwick3_000217
Pripsen mebendazole
Pripsen Mebendazole
Probes1_000013
Probes2_000149
R 17,635
R 17635
R17635
R-17635
SAM002548959
SMR000036734
SPBio_001442
SPBio_002154
Spectrum_001298
SPECTRUM1501110
Spectrum2_001401
Spectrum3_001439
Spectrum4_000416
Spectrum5_001381
Sqworm
SSL Brand of Mebendazole
SSL Brand OF mebendazole
STK093862
Streger brand OF mebendazole
Streger Brand of Mebendazole
Sufil
Surfont
Taxandria brand OF mebendazole
Taxandria Brand of Mebendazole
Tedec meiji brand OF mebendazole
Tedec Meiji Brand of Mebendazole
Telmin
TimTec1_000869
TL8002405
UNII-81G6I5V05I
Vermicidin
Vermicol
Vermidil
Vermin
Vermirax
Vermox
Vermox (TN)
Verpanyl
Versid
Wormkuur
ZINC00121541
|
|
7 |
|
Irinotecan |
Approved, Investigational |
Phase 1, Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
7-Ethyl-10-hydroxycamptothecin
97682-44-5
AC1L1U0Z
AC1Q6PGI
AC-7469
Bio-0054
Biotecan
Biotecan (TN)
BRD-K08547377-003-02-4
BSPBio_002346
C16641
C33H38N4O6
Campothecin-11
Campto
Camptosar
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
CHEBI:105985
CHEMBL481
CID60838
CP0
CPT 11
CPT-11
D08086
DB00762
|
FT-0083650
HSDB 7607
Irinophore C
irinotecan
Irinotecan
Irinotecan (INN)
Irinotecan [INN:BAN]
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan Hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan Hydrochloride Trihydrate
IRINOTECAN HYDROCHLORIDE Trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
LS-44589
NCI60_005051
NK012 Compound
NSC728073
S1198_Selleck
sn 38
sn-38
sn38 CPD
TL8006026
UNII-7673326042
|
|
8 |
|
Piperazine |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
110-85-0 |
4837 |
Synonyms:
1,4-Diazacyclohexane
1,4-Diethylenediamine
1,4-Piperazine
110-85-0
14007-05-7 (unspecified hydrobromide)
142-63-2 (hexahydrate)
142-64-3 (di-hydrochloride)
14538-56-8 (phosphate[1:1])
16832-43-2 (unspecified hydrate)
1951-97-9 (unspecified phosphate)
3597-26-0 (unspecified sulfate)
5-23-01-00030 (Beilstein Handbook Reference)
6094-40-2 (unspecified hydrochloride)
7542-23-6 (mono-hydrochloride)
8017-90-1
8027-81-4
8057-14-5 (unspecified salt)
80621_FLUKA
854880-15-2
861800-35-3
AB1003720
AC1L1J2E
AC1Q1IA7
AC1Q1IA8
AC1Q1IA9
AKOS000269028
Anthalazine
Antiren
AR-1L1009
ARONIS23910
Asca-Trol No. 3
BIDD:GT0273
BRN 0102555
C07973
CCRIS 5950
CHEBI:28568
CHEMBL1412
CID4837
D00807
DB00592
Diethylenediamine
Diethyleneimine
Dispermine
DivK1c_000038
EINECS 203-808-3
Eraverm
Eraverm (VAN)
Fluphenazine dihydrochloride
Hexahydro-1,4-diazine
Hexahydropyrazine
HMS1920H20
HMS2092A03
HMS500B20
HSDB 1093
I14-11172
IDI1_000038
InChI=1/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H
Jsp000824
KBio1_000038
KBio2_001593
KBio2_004161
KBio2_006729
KBioSS_001593
LS-517
LTBB000432
Lumbrical
MolPort-000-872-010
NCGC00094762-01
NCGC00094762-02
nchembio814-comp12
NCIOpen2_000984
NCIOpen2_000988
NCIOpen2_001024
NCIOpen2_001031
NCIOpen2_001033
NCIOpen2_001071
NCIOpen2_001073
NCIOpen2_001111
NCIOpen2_001151
NCIOpen2_001231
NCIOpen2_001262
NCIOpen2_001269
NCIOpen2_004830
|
NCIOpen2_004834
NCIOpen2_004862
NCIOpen2_004874
NCIOpen2_004904
NCIOpen2_004910
NCIOpen2_004914
NCIOpen2_004942
NCIOpen2_004952
NCIOpen2_004954
NCIOpen2_004982
NCIOpen2_004992
NCIOpen2_004994
NCIOpen2_005022
NCIOpen2_005032
NCIOpen2_005034
NCIOpen2_005062
NCIOpen2_005072
NCIOpen2_005102
NCIOpen2_005108
NCIOpen2_005145
NCIOpen2_005182
NCIOpen2_005185
NCIOpen2_005187
NCIOpen2_005200
NCIOpen2_005575
NCIOpen2_005980
NCIOpen2_009422
NINDS_000038
NSC 474
NSC474
P0446
P0447
P45907_SIAL
Piperazidine
Piperazin
Piperazin [German]
Piperazin [Germany]
Piperazina
piperazine
PIPERAZINE (HEXAHYDRATE)
Piperazine (USP)
Piperazine [UN2579] [Corrosive]
Piperazine [UN2579] [Corrosive]
Piperazine [USAN]
Piperazine anhydrous
Piperazine diacetate
Piperazine dihydrochloride
Piperazine Dihydrochloride Dihydrochloride Hydrate
Piperazine hexahydrate
Piperazine Hexa-Hydrate
Piperazine hydrate
Piperazine hydrobromide
Piperazine hydrochloride
Piperazine monohydrochloride
Piperazine phosphate
Piperazine phosphate (1:1)
Piperazine salt
Piperazine sulfate
Piperazine tartrate (1:1), (R-(r*,r*))-isomer
Piperazine tartrate, (R-(r*,r*))-isomer
Piperazine, anhydrous
piperazinium oleate
Piperazinium oleate
Pipersol
Pripsen
Pyrazine hexahydride
Pyrazine, hexahy
PZE
Spectrum_001113
SPECTRUM1500490
Spectrum5_001817
UN2579
UNII-1RTM4PAL0V
Upixon
Uvilon
Vermex
Vermizine
Vermizine (TN)
WLN: T6M DMTJ
Worm-A-Ton
Worm-away
Wurmirazin
|
|
9 |
|
Bevacizumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
10 |
|
Trioxsalen |
Approved |
Phase 2 |
|
3902-71-4 |
5585 |
Synonyms:
2',4,8-Trimethylpsoralen
2,5,9-Trimethyl-7H-furo(3,2-g)benzopyran-7-one
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylate, delta-lactone
6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylate, δ-lactone
6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylate, delta-lactone
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
6-Hydroxy-β,2,7-trimethyl-5-benzofuranacrylate, δ-lactone
|
6-hydroxy-β,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone
6-Hydroxy-β,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone
ICN brand OF trioxsalen
Trimethylpsoralen
Trioxisaleno
Trioxisalenum
Trioxsalen
Trioxysalen
Trioxysalene
Trioxysalenum
Trisoralen
|
|
11 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
12 |
|
Etoposide phosphate |
|
Phase 2 |
|
|
|
13 |
|
Liposomal doxorubicin |
|
Phase 2 |
|
|
31703 |
Synonyms:
|
LipoDox
liposomal doxorubicin
Pegylated Liposomal Doxorubicin Hydrochloride
|
|
14 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
15 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
16 |
|
Interferon alpha-2 |
|
Phase 2 |
|
|
|
17 |
|
interferons |
|
Phase 2 |
|
|
|
18 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
19 |
|
Interferon-alpha |
|
Phase 2 |
|
|
|
20 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
21 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
22 |
|
Anthelmintics |
|
Phase 1, Phase 2 |
|
|
|
23 |
|
Citrate |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
Tubulin Modulators |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Angiogenesis Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
DMP 777 |
|
Phase 1, Phase 2 |
|
157341-41-8 |
|
27 |
|
Antiparasitic Agents |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
Anticonvulsants |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
Piperazine citrate |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
Antimitotic Agents |
|
Phase 1, Phase 2 |
|
|
|
31 |
|
Antineoplastic Agents, Immunological |
|
Phase 1, Phase 2 |
|
|
|
32 |
|
topoisomerase I inhibitors |
|
Phase 1, Phase 2 |
|
|
|
33 |
|
Photosensitizing Agents |
|
Phase 2 |
|
|
|
34 |
|
Dihematoporphyrin Ether |
|
Phase 2 |
|
|
|
35 |
|
Dermatologic Agents |
|
Phase 2 |
|
|
|
36 |
|
Hematoporphyrin Derivative |
|
Phase 2 |
|
|
|
37 |
|
Ether |
|
Phase 2 |
|
|
|
38 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
39 |
|
Entinostat |
Investigational |
Phase 1 |
|
209783-80-2 |
|
Synonyms:
Entinostat
Entinostatum
MS-275
|
N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide
N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
SNDX-275
|
|
40 |
|
Histone Deacetylase Inhibitors |
|
Phase 1 |
|
|
|
41 |
|
Dopamine |
Approved |
|
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
42 |
|
Tyrosine |
Approved, Investigational, Nutraceutical |
|
|
60-18-4 |
6057 |
Synonyms:
(-)-a-amino-P-Hydroxyhydrocinnamate
(-)-a-amino-P-Hydroxyhydrocinnamic acid
(-)-alpha-amino-P-Hydroxyhydrocinnamate
(-)-alpha-amino-P-Hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-α-amino-P-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-α-amino-P-hydroxyhydrocinnamic acid
(2S)-2-amino-3-(4-Hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-amino-3-(4-Hydroxyphenyl)propanoic acid
(S)-(-)-Tyrosine
(S)-2-Amino-3-(4-hydroxyphenyl)propionic acid
(S)-2-amino-3-(P-Hydroxyphenyl)propionate
(S)-2-amino-3-(P-Hydroxyphenyl)propionic acid
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-3-(P-Hydroxyphenyl)alanine
(S)-a-amino-4-Hydroxybenzenepropanoate
(S)-a-amino-4-Hydroxy-benzenepropanoate
(S)-a-amino-4-Hydroxybenzenepropanoic acid
(S)-a-amino-4-Hydroxy-benzenepropanoic acid
(S)-alpha-amino-4-Hydroxybenzenepropanoate
(S)-alpha-amino-4-Hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-amino-4-Hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoic acid
(S)-Tyrosine
(S)-α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
140-43-2
1991-85-1
25619-78-7
2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionic acid
2csm
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
46209-14-7
4-hydroxy-L-phenylalanine
4-Hydroxy-L-phenylalanine
4ts1
55520-40-6
60-18-4
93829_FLUKA
93829_SIGMA
AB1002647
AC-11295
AC1L1LPI
AC1Q4U7L
AC1Q4U7M
AI3-09055
alpha-Amino-beta-(4-hydroxyphenyl)propionic acid
AR-1J3457
BB_NC-1194
Benzenepropanoate
Benzenepropanoic acid
beta-(p-Hydroxyphenyl)alanine
bmse000051
C00082
CHEBI:17895
CHEMBL925
CID6057
D00022
DB00135
|
DB03839
DD69927C-C6A8-4BC6-8E9A-0AB423B176E7
DTY
EINECS 200-460-4
FEMA No. 3736
Free-Form L-Tyrosine
HSDB 2003
H-Tyr-OH
L Tyrosine
L-(-)-Tyrosine
L-2-Amino-3-p-hydroxyphenylpropanoic acid
L-p-Tyrosine
L-P-Tyrosine
LS-2336
L-Tyrosin
L-tyrosine
L-Tyrosine (9CI)
L-Tyrosine (JAN)
L-Tyrosine hydrochloride
L-Tyrosine, homopolymer
L-Tyrosine, monomer
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours
MolPort-001-792-016
NCGC00159350-02
NCGC00159350-03
nchembio.105-comp1
nchembio.121-comp7
nchembio.186-comp84
nchembio.284-comp7
nchembio816-comp11
NSC 82624
Para tyrosine
Para-tyrosine
p-Tyrosine
P-Tyrosine
Rxosine
T0550
T3754_SIAL
T4321_SIAL
T4321_SIGMA
T8566_SIGMA
tirosina
Tirosina
Tirosina [Spanish]
tyr
Tyr
TYR NH3+ COOH
tyrosine
Tyrosine
TYROSINE
Tyrosine (USP/INN)
Tyrosine (VAN)
Tyrosine [USAN:INN]
Tyrosine Power
Tyrosine, L- (8CI)
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Tyrosinum [Latin]
UNII-42HK56048U
W373605_ALDRICH
Y
|
|
43 |
|
Fluorodeoxyglucose F18 |
|
|
|
|
|
44 |
|
Fluorides |
|
|
|
|
|
45 |
|
Neurotransmitter Agents |
|
|
|
|
|
46 |
|
Dihydroxyphenylalanine |
|
|
|
|
|
47 |
|
Dopamine Agents |
|
|
|
|
|
Interventional clinical trials:
(show all 17)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized Phase 3 Study of Antineoplastons A10 and AS2-1 vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma After Carboplatin or Cisplatin Therapy |
Withdrawn |
NCT01260103 |
Phase 3 |
Temozolomide;ANP Therapy |
2 |
Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Children With Visual Pathway Glioma |
Completed |
NCT00003477 |
Phase 2 |
Antineoplaston therapy (Atengenal + Astugenal) |
3 |
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors |
Recruiting |
NCT02372409 |
Phase 2 |
Doxorubicin;Etoposide |
4 |
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF) |
Recruiting |
NCT02839720 |
Phase 2 |
Selumetinib;Selumetinib Sulfate |
5 |
A Phase II Study Of Pegylated Interferon ALFA-2b in Children With Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas |
Recruiting |
NCT02343224 |
Phase 2 |
Pegylated interferon alpha-2b |
6 |
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma |
Recruiting |
NCT03326388 |
Phase 1, Phase 2 |
Selumetinib |
7 |
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas |
Recruiting |
NCT01837862 |
Phase 1, Phase 2 |
Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan |
8 |
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma |
Recruiting |
NCT01089101 |
Phase 1, Phase 2 |
Selumetinib |
9 |
A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults |
Terminated |
NCT01966809 |
Phase 2 |
Photofrin photodynamic therapy. |
10 |
Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study |
Completed |
NCT01682746 |
Phase 1 |
Photofrin (porfimer sodium) & photodynamic therapy. |
11 |
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma |
Active, not recruiting |
NCT02780804 |
Phase 1 |
Entinostat |
12 |
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies |
Completed |
NCT00898755 |
|
|
13 |
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults With Neurofibromatosis Type 1 |
Recruiting |
NCT00924196 |
|
|
14 |
Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography- Magnetic Resonance Imaging (FDG-PET-MRI) in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) |
Active, not recruiting |
NCT01800032 |
|
|
15 |
18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas |
Terminated |
NCT02175745 |
|
18F-fluoro-dihydroxyphenylalanine |
16 |
Feasibility of Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas |
Withdrawn |
NCT02976441 |
Early Phase 1 |
Temozolomide |
17 |
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
Withdrawn |
NCT02194452 |
|
|
|